Jaguar Health, Inc. (JAGX) is a publicly traded Healthcare sector company. As of May 21, 2026, JAGX trades at $3.51 with a market cap of $1.90M and a P/E ratio of -0.16. JAGX moved +0.00% today. Year to date, JAGX is -88.80%; over the trailing twelve months it is -98.02%. Its 52-week range spans $2.53 to $1,121.59. Rallies surfaces JAGX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Jaguar Health Q1 Revenue Jumps 816% to $20.3M on $19M License Deal: Jaguar Health’s Q1 2026 net revenue surged 816% year-over-year to $20.27 million, driven by $19 million in license and grant fees from the Future Pak agreement. Operating income turned positive at $10.18 million, while net loss narrowed to $7.02 million and crofelemer rare-disease development continues.
| Metric | Value |
|---|---|
| Price | $3.51 |
| Market Cap | $1.90M |
| P/E Ratio | -0.16 |
| EPS | $-22.97 |
| Dividend Yield | 0.00% |
| 52-Week High | $1,121.59 |
| 52-Week Low | $2.53 |
| Volume | 29.76K |
| Avg Volume | 0 |
| Revenue (TTM) | $11.51M |
| Net Income | $-54.00M |
| Gross Margin | 67.21% |
JAGX analyst coverage data. Average price target: $0.00.